<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Contrastive Geometric Learning Unlocks Unified Structure- and Ligand-Based Drug Design - Health AI Hub</title>
    <meta name="description" content="This paper introduces ConGLUDe, a novel contrastive geometric model that unifies structure-based and ligand-based computational drug design. By integrating prot">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>Contrastive Geometric Learning Unlocks Unified Structure- and Ligand-Based Drug Design</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2601.09693v1" target="_blank">2601.09693v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2026-01-14
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Lisa Schneckenreiter, Sohvi Luukkonen, Lukas Friedrich, Daniel Kuhn, G√ºnter Klambauer
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.LG, stat.ML
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.95 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2601.09693v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2601.09693v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper introduces ConGLUDe, a novel contrastive geometric model that unifies structure-based and ligand-based computational drug design. By integrating protein and ligand representations and implicitly predicting binding sites without predefined pockets, ConGLUDe achieves state-of-the-art performance in virtual screening, target fishing, and ligand-conditioned pocket prediction across diverse benchmarks.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This unified computational drug design platform has the potential to significantly accelerate and improve the efficiency of early-stage drug discovery by more accurately identifying drug candidates and their targets, ultimately contributing to the faster development of new therapies.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>This AI application enhances the drug discovery process by providing a unified computational model for identifying potential drug candidates, predicting their binding sites, and elucidating their targets. It facilitates more efficient and accurate virtual screening, lead optimization, and rational drug design, thereby accelerating the development of new medicines and therapies.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>ConGLUDe is a single contrastive geometric model designed to unify structure-based (SBDD) and ligand-based (LBDD) drug design paradigms.</li>
                    
                    <li>It employs a geometric protein encoder that generates whole-protein representations and implicit embeddings of predicted binding sites, coupled with a fast ligand encoder.</li>
                    
                    <li>The model explicitly removes the traditional need for pre-defined binding pockets, streamlining the drug design process.</li>
                    
                    <li>Training is conducted jointly on diverse data sources: protein-ligand complexes and large-scale bioactivity data, leveraging contrastive learning for alignment.</li>
                    
                    <li>ConGLUDe supports multiple critical drug design tasks, including virtual screening, target fishing, and ligand-conditioned pocket prediction.</li>
                    
                    <li>It achieves state-of-the-art zero-shot virtual screening performance, particularly in scenarios lacking explicit binding pocket information.</li>
                    
                    <li>The model substantially outperforms existing methods on challenging target fishing tasks and demonstrates competitive performance in ligand-conditioned pocket selection, highlighting the benefits of unified training.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>ConGLUDe utilizes a single contrastive geometric learning model. It integrates a geometric protein encoder that produces whole-protein representations and implicitly embedded binding sites, with a fast ligand encoder. The core mechanism involves contrastive learning to align ligands with both global protein representations and multiple candidate binding sites. The model is jointly trained using protein-ligand complexes and large-scale bioactivity data.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>ConGLUDe demonstrates state-of-the-art zero-shot virtual screening performance, specifically in settings where no binding pocket information is provided. It substantially outperforms existing methods on a challenging target fishing task and achieves competitive results in ligand-conditioned pocket selection. These findings underscore the advantages of its unified structure-ligand training approach.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>By providing a more efficient, accurate, and versatile computational platform for drug discovery, ConGLUDe can significantly shorten the timelines and reduce the costs associated with identifying novel drug candidates. This could lead to a faster pipeline for new therapeutic agents, potentially impacting the development of treatments for a wide array of diseases by improving the precision and speed of lead compound identification and optimization.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract does not explicitly state any limitations of the ConGLUDe model or its current implementation.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The paper positions ConGLUDe as a "step toward general-purpose foundation models for drug discovery," suggesting future work could focus on further expanding its capabilities and generalizability to serve as a foundational AI model for a broader range of drug discovery and development tasks.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Pharmacology</span>
                    
                    <span class="tag">Drug Discovery</span>
                    
                    <span class="tag">Medicinal Chemistry</span>
                    
                    <span class="tag">Computational Biology</span>
                    
                    <span class="tag">Structural Biology</span>
                    
                    <span class="tag">Biotechnology</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Drug design</span>
                    
                    <span class="tag tag-keyword">Virtual screening</span>
                    
                    <span class="tag tag-keyword">Target fishing</span>
                    
                    <span class="tag tag-keyword">Contrastive learning</span>
                    
                    <span class="tag tag-keyword">Geometric deep learning</span>
                    
                    <span class="tag tag-keyword">Protein-ligand interaction</span>
                    
                    <span class="tag tag-keyword">Artificial intelligence</span>
                    
                    <span class="tag tag-keyword">Computational drug discovery</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Structure-based and ligand-based computational drug design have traditionally relied on disjoint data sources and modeling assumptions, limiting their joint use at scale. In this work, we introduce Contrastive Geometric Learning for Unified Computational Drug Design (ConGLUDe), a single contrastive geometric model that unifies structure- and ligand-based training. ConGLUDe couples a geometric protein encoder that produces whole-protein representations and implicit embeddings of predicted binding sites with a fast ligand encoder, removing the need for pre-defined pockets. By aligning ligands with both global protein representations and multiple candidate binding sites through contrastive learning, ConGLUDe supports ligand-conditioned pocket prediction in addition to virtual screening and target fishing, while being trained jointly on protein-ligand complexes and large-scale bioactivity data. Across diverse benchmarks, ConGLUDe achieves state-of-the-art zero-shot virtual screening performance in settings where no binding pocket information is provided as input, substantially outperforms existing methods on a challenging target fishing task, and demonstrates competitive ligand-conditioned pocket selection. These results highlight the advantages of unified structure-ligand training and position ConGLUDe as a step toward general-purpose foundation models for drug discovery.</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>ELLIS ML4Molecules Workshop 2025, ELLIS Unconference, Copenhagen 2025</p>
            </section>
            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>